Childhood exposure to bacterial toxin may be triggering colorectal cancer epidemic among the young
On Apr. 23, 2025, researchers from the Wellcome Sanger Institute, University of California San Diego and their collaborators…
U.S. Surgeon General Issues New Advisory on Link Between Alcohol and Cancer Risk
On Jan. 3, 2025, the U.S. General Dr. Vivek Murthy released a new Surgeon General’s Advisory on Alcohol…
Biotechnology | Diagnostics | Disease | FDA | Oncology | Therapeutics
U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
On Dec. 20, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved BRAFTOVI® (encorafenib)…
Generation X and Millennials in U.S. Have Higher Risk of Developing 17 Cancers Compared to Older Generations
On Jul. 31, 2024, a large study led by researchers at the American Cancer Society (ACS) suggested incidence…
Clinical study of a blood test shows 83% accuracy for detecting colorectal cancer
On Mar. 13, 2024, the Fred Hutchinson Cancer Center announced that a blood test intended for screening for…
Mayo Clinic study found colon cancer driven by hereditary gene mutations in 1 in 6 patients
On Apr. 19, 2021, the Mayo Clinic announced a study that bolstered evidence that colorectal cancer is often…
Biotechnology | Diagnostics | Disease | Oncology | Radiology | Therapeutics
National Cancer Institute scientists reported low-dose drug combination cuts risk of colon polyp recurrence
May 4, 2018, scientists from the National Cancer Institute (NCI) reported that an analysis of a prevention clinical…
Biotechnology | FDA | Oncology | Therapeutics
The monoclonal antibody cetuximab (Erbitux) was approved by the FDA for the treatment of metastatic colorectal cancer
On Feb. 1, 2004, the U.S. Food and Drug Administration (FDA) announced it had approved Cetuximab, a recombinant…
Death rates from the lung, breast, prostate, and colorectal cancers continued to decline in the late 1990s
On Sept. 3, 2003, the death rates from the four most common cancers, – lung, breast, prostate, and…
Two randomized controlled trials showed that taking aspirin daily for as little as three years reduces the development of colorectal polyps
In 2003, two randomized controlled trials showed that taking aspirin daily for as little as three years reduces…
National Colorectal Cancer Awareness Month was established
On Nov. 19, 1999, National Colorectal Cancer Awareness Month was established with a declaration by the U.S. Senate,…
Biotechnology | Diagnostics | Disease | FDA | Oncology
The FDA approved another topoisomerase 1 inhibitor for the treatment of metastatic colorectal cancer
In June 1996, the Food and Drug Administration (FDA) first approved irinotecan for the treatment of patients with…
Colon cancer gene was identified
On Dec. 2, 1993, Dana-Farber scientists identified the gene that causes an inherited form of colon cancer, which…
The Prostate, Lung, Colorectal, and Ovarian trial began recruiting 148,000 men and women, ages 55-74
In 1993, the Prostate, Lung, Colorectal, and Ovarian trial was launched The trial was designed to determine whether…
Washington University School of Medicine announced as a participating site for the prostate, lung, colorectal, and ovarian cancers (PLCO study)
In 1993, the Washington University School of Medicine announced that it was a participating site for the prostate,…